Raymond James Financial’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-59,357
Closed -$3.19M – 5537
2026
Q2
$3.19M Buy
59,357
+14,218
+31% +$629K ﹤0.01% 3120
2026
Q1
$2.18M Buy
45,139
+751
+2% +$51.4K ﹤0.01% 3298
2025
Q4
$3.09M Buy
+44,388
New +$1.81M ﹤0.01% 2911
2025
Q3
– Sell
-6,229
Closed -$129K – 5687
2025
Q2
$129K Buy
+6,229
New +$137K ﹤0.01% 4734

Other funds holding GPCR

Raymond James Financial's GPCR Position: Q3 2026 in Review

Raymond James Financial sold out of Structure Therapeutics (GPCR) in Q3 2026, closing a stake of 59,357 shares — an estimated $3.19M sold.

Raymond James Financial first reported a position in GPCR in Q2 2025 and held it in 4 quarters. The position peaked at $3.19M in Q2 2026. 169 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Raymond James Financial reported no remaining Structure Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Raymond James Financial sold 59,357 Structure Therapeutics shares in Q3 2026, an estimated $3.19M.
  • Raymond James Financial first reported a position in Structure Therapeutics in Q2 2025 and held it in 4 quarters.
  • Raymond James Financial's Structure Therapeutics position peaked at $3.19M in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.